323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I

Emicizumab for severe von willebrand disease VWD The EmiVWD study enrollment 2025

Efficacy and safety of  RCD pulse regimen for acquired Hemophilia A

Aquired hemophilla a after covid 19 infection in an 5 week old infant

Treatment of type 1 plasminogen deficiency in women and girls with reproductive tract lesions Pharmacokinetics and clinical outcomes with plasminogen therapy

Prevalence and management of iron deficiency in patients with bleeding disorders A single center retrospective cohort study

Congenital factor II deficiency presenting with recurrent thrombosis

Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease Interim results from a phase 3 multicenter study and a phase 3b continuation study

EASIX guided risk stratification of severe coagulopathy and early mortality among newly diagnosed acute myeloid leukaemia with APL like phenotype

Tissue factor bearing microparticles drive thromboinflammation and predict DIC and mortality in sepsis Results from the roadmap sepsis study

A retrospective analysis of the safety and effectiveness of recombinant von willebrand factor in children with von willebrand disease undergoing surgery

Blood group o and a lower endogenous thrombin potential are associated with increased risk for future bleeding after hemostatic challenges in bleeding disorder of unknown cause